MeiraGTx is developing AAV-AQP1 as a potential treatment for xerostomia caused by Sjogren’s syndrome, a disease affecting more than two million people in the United States. Sjogren’s syndrome is an autoimmune disease in which a patient’s immune system may target the salivary glands. Chronic inflammation of the salivary glands results in long term damage and chronic xerostomia in many Sjogren’s patients.